Zentalis Pharmaceuticals ... (ZNTL)
1.78
0.02 (1.14%)
At close: Mar 27, 2025, 3:59 PM
1.79
0.28%
After-hours: Mar 27, 2025, 05:07 PM EDT
1.14% (1D)
| Bid | 1.74 |
| Market Cap | 127.21M |
| Revenue (ttm) | 42.76M |
| Net Income (ttm) | -179.67M |
| EPS (ttm) | -2.33 |
| PE Ratio (ttm) | -0.77 |
| Forward PE | -0.74 |
| Analyst | Hold |
| Ask | 1.84 |
| Volume | 924,872 |
| Avg. Volume (20D) | 1,827,089 |
| Open | 1.86 |
| Previous Close | 1.76 |
| Day's Range | 1.74 - 2.01 |
| 52-Week Range | 1.61 - 16.27 |
| Beta | 1.75 |
About ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 3, 2020
Employees 124
Stock Exchange NASDAQ
Ticker Symbol ZNTL
Website https://zentalis.com
Analyst Forecast
According to 8 analyst ratings, the average rating for ZNTL stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 348.18% from the latest price.
Stock Forecasts1 month ago
-21.25%
Zentalis Pharmaceuticals shares are trading lower....
Unlock content with
Pro Subscription
2 months ago
-1.08%
Zentalis Pharmaceuticals shares are trading higher after the company announced that the FDA has granted Fast Track Designation to azenosertib for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
